Medivation rises on upbeat Xtandi urologist survey

|By:, SA News Editor

Medivation (MDVN +2.9%) is trading notably higher in early action.

The move looks to be attributable to a UBS urologist survey.

From the note: "Xtandi's safety profile is closer to other drugs commonly prescribed by urologists ... suggesting they may favor it vs. Johnson & Johnson's (JNJ) Zytiga."